JP2012149081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012149081A5 JP2012149081A5 JP2012073369A JP2012073369A JP2012149081A5 JP 2012149081 A5 JP2012149081 A5 JP 2012149081A5 JP 2012073369 A JP2012073369 A JP 2012073369A JP 2012073369 A JP2012073369 A JP 2012073369A JP 2012149081 A5 JP2012149081 A5 JP 2012149081A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- disease
- pharmaceutical composition
- tissue
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 85
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 36
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 210000001519 tissue Anatomy 0.000 claims 26
- 230000004069 differentiation Effects 0.000 claims 22
- 201000010099 disease Diseases 0.000 claims 22
- 239000000523 sample Substances 0.000 claims 18
- 238000000034 method Methods 0.000 claims 17
- 208000035475 disorder Diseases 0.000 claims 14
- 102000005962 receptors Human genes 0.000 claims 14
- 108020003175 receptors Proteins 0.000 claims 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 230000017423 tissue regeneration Effects 0.000 claims 5
- 208000020084 Bone disease Diseases 0.000 claims 4
- 230000005779 cell damage Effects 0.000 claims 4
- 208000037887 cell injury Diseases 0.000 claims 4
- 239000013068 control sample Substances 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 4
- 230000003412 degenerative effect Effects 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 210000000988 bone and bone Anatomy 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000008859 change Effects 0.000 claims 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 238000005481 NMR spectroscopy Methods 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 238000002441 X-ray diffraction Methods 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 229940088710 antibiotic agent Drugs 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940034982 antineoplastic agent Drugs 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000005540 biological transmission Effects 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 210000002216 heart Anatomy 0.000 claims 2
- 230000009459 hedgehog signaling Effects 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 238000002513 implantation Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 238000004949 mass spectrometry Methods 0.000 claims 2
- 230000000921 morphogenic effect Effects 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000005084 renal tissue Anatomy 0.000 claims 2
- 230000001850 reproductive effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 210000004268 dentin Anatomy 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000000944 nerve tissue Anatomy 0.000 claims 1
- -1 nucleic acid compound Chemical class 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 125000000542 sulfonic acid group Chemical group 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71901405P | 2005-09-20 | 2005-09-20 | |
| US60/719,014 | 2005-09-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532384A Division JP2009508532A (ja) | 2005-09-20 | 2006-09-20 | Ｔｄｆ関連化合物およびその類似体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014010456A Division JP2014132900A (ja) | 2005-09-20 | 2014-01-23 | Ｔｄｆ関連化合物およびその類似体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012149081A JP2012149081A (ja) | 2012-08-09 |
| JP2012149081A5 true JP2012149081A5 (enExample) | 2013-05-30 |
Family
ID=37889535
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532384A Pending JP2009508532A (ja) | 2005-09-20 | 2006-09-20 | Ｔｄｆ関連化合物およびその類似体 |
| JP2012073369A Withdrawn JP2012149081A (ja) | 2005-09-20 | 2012-03-28 | Ｔｄｆ関連化合物およびその類似体 |
| JP2014010456A Pending JP2014132900A (ja) | 2005-09-20 | 2014-01-23 | Ｔｄｆ関連化合物およびその類似体 |
| JP2015206139A Pending JP2016047829A (ja) | 2005-09-20 | 2015-10-20 | Ｔｄｆ関連化合物およびその類似体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008532384A Pending JP2009508532A (ja) | 2005-09-20 | 2006-09-20 | Ｔｄｆ関連化合物およびその類似体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014010456A Pending JP2014132900A (ja) | 2005-09-20 | 2014-01-23 | Ｔｄｆ関連化合物およびその類似体 |
| JP2015206139A Pending JP2016047829A (ja) | 2005-09-20 | 2015-10-20 | Ｔｄｆ関連化合物およびその類似体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8299212B2 (enExample) |
| EP (3) | EP2927241A1 (enExample) |
| JP (4) | JP2009508532A (enExample) |
| AU (1) | AU2006292147B2 (enExample) |
| CA (2) | CA2623415A1 (enExample) |
| CY (1) | CY1116742T1 (enExample) |
| DK (1) | DK2497780T3 (enExample) |
| ES (1) | ES2537527T3 (enExample) |
| HU (1) | HUE026634T2 (enExample) |
| PL (1) | PL2497780T3 (enExample) |
| PT (1) | PT2497780E (enExample) |
| SI (1) | SI2497780T1 (enExample) |
| WO (1) | WO2007035872A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299212B2 (en) | 2005-09-20 | 2012-10-30 | Thrasos Therapeutics, Inc. | TDF-related compounds and analogs thereof, analogs and bioactive fragments |
| US8995742B1 (en) * | 2009-11-10 | 2015-03-31 | Us Synthetic Corporation | Systems and methods for evaluation of a superabrasive material |
| WO2013013085A2 (en) * | 2011-07-19 | 2013-01-24 | Thrasos Innovation, Inc. | Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis |
| EP3613765B1 (en) | 2012-08-03 | 2024-10-02 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
| WO2015164800A2 (en) * | 2014-04-24 | 2015-10-29 | University Of Central Florida Research Foundation, Inc. | Compositions and methods for modulating polarization of monocytes |
| US20160137714A1 (en) * | 2014-11-12 | 2016-05-19 | Thrasos Innovation, Inc. | Peptides with enhanced stability and their use in methods for treating diseases |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| AU2019366366B2 (en) * | 2018-10-22 | 2025-09-25 | William D. Carlson | Therapeutic combinations of TDFRPs and additional agents and methods of use |
| CA3212468A1 (en) * | 2021-03-16 | 2022-09-22 | William D. Carlson | Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis |
| WO2023049274A2 (en) * | 2021-09-22 | 2023-03-30 | Therapeutics By Design, LLC | Methods of treating cancer |
| KR102749109B1 (ko) * | 2021-11-04 | 2025-01-03 | (주)케어젠 | 생리 활성을 갖는 펩타이드 및 그의 용도 |
| EP4601667A1 (en) | 2022-10-10 | 2025-08-20 | Therapeutics by Design, LLC | Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury |
| CN120838344B (zh) * | 2025-09-19 | 2025-11-28 | 安徽天铁锂电新能源有限公司 | 粗碳酸锂提纯电池级碳酸锂的装置及其提纯方法 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4768523A (en) | 1981-04-29 | 1988-09-06 | Lifecore Biomedical, Inc. | Hydrogel adhesive |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| DE3751873T2 (de) | 1986-04-09 | 1997-02-13 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5041138A (en) | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
| GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| US5041126A (en) | 1987-03-13 | 1991-08-20 | Cook Incorporated | Endovascular stent and delivery system |
| US5092871A (en) | 1987-03-13 | 1992-03-03 | Brown University Research Foundation | Electrically-charged nerve guidance channels |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US5213580A (en) | 1988-08-24 | 1993-05-25 | Endoluminal Therapeutics, Inc. | Biodegradable polymeric endoluminal sealing process |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US4955892A (en) | 1988-10-24 | 1990-09-11 | Louisiana State University | Neural cell adhesion protein nerve prosthesis |
| US5089606A (en) | 1989-01-24 | 1992-02-18 | Minnesota Mining And Manufacturing Company | Water-insoluble polysaccharide hydrogel foam for medical applications |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| JPH085780B2 (ja) | 1989-04-28 | 1996-01-24 | 呉羽化学工業株式会社 | 変形性関節症治療剤 |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| US5052998A (en) | 1990-04-04 | 1991-10-01 | Zimmon David S | Indwelling stent and method of use |
| US5064435A (en) | 1990-06-28 | 1991-11-12 | Schneider (Usa) Inc. | Self-expanding prosthesis having stable axial length |
| WO1992000968A1 (en) | 1990-07-10 | 1992-01-23 | Smithkline Beecham Corporation | Oxamides |
| EP0573608A1 (en) | 1991-02-07 | 1993-12-15 | Molecumetics, Ltd. | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| DK0575555T3 (da) | 1991-03-11 | 2001-11-05 | Curis Inc | Proteininduceret morfogenese |
| US5147370A (en) | 1991-06-12 | 1992-09-15 | Mcnamara Thomas O | Nitinol stent for hollow body conduits |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| EP1637156A1 (en) | 1991-08-30 | 2006-03-22 | Curis, Inc. | Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases |
| DE69231062T3 (de) | 1991-08-30 | 2004-07-29 | Creative Biomolecules, Inc., Hopkinton | Morphogen-induzierte Modulation von entzündlichen Antworten |
| US5525519A (en) | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| US5176626A (en) | 1992-01-15 | 1993-01-05 | Wilson-Cook Medical, Inc. | Indwelling stent |
| US5683448A (en) | 1992-02-21 | 1997-11-04 | Boston Scientific Technology, Inc. | Intraluminal stent and graft |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| AU681594B2 (en) | 1992-07-31 | 1997-09-04 | Stryker Corporation | Morphogen-induced nerve regeneration and repair |
| EP0680334B1 (en) | 1992-09-15 | 2000-12-13 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
| CA2144514C (en) | 1992-09-16 | 2002-03-26 | Thangavel Kuberasampath | Morphogen-induced liver regeneration |
| JP3537141B2 (ja) | 1992-10-30 | 2004-06-14 | ザ ゼネラル ホスピタル コーポレーション | 新種蛋白質分離のための相互作用を用いる補捉システム |
| NZ257631A (en) | 1992-11-17 | 1996-03-26 | Ludwig Inst Cancer Res | Serine/threonine kinase domain-containing protein, dna and hosts therefor |
| US5637480A (en) * | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| US5579591A (en) | 1993-06-29 | 1996-12-03 | Limited Responsibility Company Frontier | Footwear for patients of osteoarthritis of the knee |
| NZ278765A (en) | 1993-12-30 | 1998-05-27 | Harvard College | Vertebrate proteins involved in spatial arrangements of differentiated tissues called hedgehog proteins, their production and use |
| EP0756628B1 (en) | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogenic protein-specific cell surface receptors and uses therefor |
| US5614609A (en) | 1994-10-20 | 1997-03-25 | Carlos F. Ibanez | Serine threonine kinase receptor |
| US6306622B1 (en) | 1994-11-04 | 2001-10-23 | The Procter & Gamble Co. | cDNA encoding a BMP type II receptor |
| US6210899B1 (en) | 1994-11-04 | 2001-04-03 | The Procter & Gamble Company | Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor |
| US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5681274A (en) | 1995-03-31 | 1997-10-28 | Boston Scientific Corporation | Variable length uretheral stent |
| US5569676A (en) | 1995-05-24 | 1996-10-29 | Diehl; Harry W. | Method for the treatment of osteoarthritis |
| JP2000514777A (ja) | 1995-08-14 | 2000-11-07 | クリエイティブ バイオモレキュールズ，インコーポレイテッド | 骨形成タンパク質（ｏｐ−１）およびそのアナログの細胞表面レセプターａｌｋ−１およびそのアナログへの結合 |
| US5989827A (en) | 1995-11-14 | 1999-11-23 | Abbott Laboratories | Use of nuclear magnetic resonance to design ligands to target biomolecules |
| US6273598B1 (en) * | 1996-01-22 | 2001-08-14 | Creative Biomolecules, Inc. | Computer system and methods for producing morphogen analogs of human OP-1 |
| ATE493141T1 (de) | 1996-03-22 | 2011-01-15 | Stryker Corp | Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns |
| WO1998040747A1 (en) | 1997-03-07 | 1998-09-17 | Mount Sinai Hospital Corporation | Methods to diagnose a required regulation of trophoblast invasion |
| US6818440B2 (en) | 1997-04-28 | 2004-11-16 | Sugen, Inc. | Diagnosis and treatment of alk-7 related disorders |
| US6111066A (en) | 1997-09-02 | 2000-08-29 | Martek Biosciences Corporation | Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains |
| US6198281B1 (en) | 1997-11-12 | 2001-03-06 | The Research Foundation Of State University Of New York | NMR spectroscopy of large proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP3561738B2 (ja) | 1998-06-02 | 2004-09-02 | 株式会社リガク | Ｂｒａｇｇ反射自動選出方法および装置並びに結晶方位自動決定方法およびシステム |
| EP1100872A1 (en) | 1998-07-24 | 2001-05-23 | Carnegie Institution Of Washington | Method for maintenance and propagation of germline stem cells using members of the tgf-beta family of growth factors |
| JP2002524528A (ja) | 1998-09-11 | 2002-08-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法 |
| US6329184B1 (en) | 1998-12-18 | 2001-12-11 | Pharmacia & Upjohn Ab | Crystalline form of activated tartrate-resistant and purple acid phosphatase |
| US6444802B1 (en) * | 1999-09-30 | 2002-09-03 | Millenium Pharmaceuticals, Inc. | Human aminopeptidase |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US6468346B2 (en) | 1999-12-10 | 2002-10-22 | Bsi Proteomics Corporation | Applying x-ray topography and diffractometry to improve protein crystal growth |
| US20040171533A1 (en) | 2000-02-29 | 2004-09-02 | Barbara Zehentner | Methods and compositions for regulating adiopocytes |
| US6669722B2 (en) | 2000-09-22 | 2003-12-30 | Cordis Corporation | Stent with optimal strength and radiopacity characteristics |
| EP1334442A2 (en) | 2000-11-06 | 2003-08-13 | Thrasos, Inc. | Computer method and apparatus for classifying objects |
| EP1334365B1 (en) | 2000-11-06 | 2007-02-21 | Thrasos, Inc. | Screening methods for bone morphogenetic mimetics |
| US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
| US6679911B2 (en) | 2001-03-01 | 2004-01-20 | Cordis Corporation | Flexible stent |
| EP1383867A2 (en) | 2001-03-23 | 2004-01-28 | Axordia Limited | Stem cell differentiation |
| US6673106B2 (en) | 2001-06-14 | 2004-01-06 | Cordis Neurovascular, Inc. | Intravascular stent device |
| US20030103959A1 (en) | 2001-06-22 | 2003-06-05 | Hughes Paul E. | Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor |
| WO2003106972A2 (en) * | 2002-06-17 | 2003-12-24 | Thrasos, Inc. | Multiple domain tdf-related compounds and analogs thereof |
| EP1572950B1 (en) * | 2002-06-17 | 2012-10-10 | Thrasos, Inc. | Single domain tdf-related compounds and analogs thereof |
| EP2789342A1 (en) * | 2004-06-17 | 2014-10-15 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| US8299212B2 (en) * | 2005-09-20 | 2012-10-30 | Thrasos Therapeutics, Inc. | TDF-related compounds and analogs thereof, analogs and bioactive fragments |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2006
- 2006-09-20 US US11/992,161 patent/US8299212B2/en not_active Expired - Fee Related
- 2006-09-20 WO PCT/US2006/036830 patent/WO2007035872A2/en not_active Ceased
- 2006-09-20 SI SI200631943T patent/SI2497780T1/sl unknown
- 2006-09-20 EP EP15155425.0A patent/EP2927241A1/en not_active Withdrawn
- 2006-09-20 CA CA 2623415 patent/CA2623415A1/en not_active Abandoned
- 2006-09-20 EP EP06815103A patent/EP1945258A4/en not_active Withdrawn
- 2006-09-20 CA CA 2863125 patent/CA2863125A1/en not_active Abandoned
- 2006-09-20 AU AU2006292147A patent/AU2006292147B2/en not_active Ceased
- 2006-09-20 HU HUE12171205A patent/HUE026634T2/en unknown
- 2006-09-20 PL PL12171205T patent/PL2497780T3/pl unknown
- 2006-09-20 PT PT121712053T patent/PT2497780E/pt unknown
- 2006-09-20 ES ES12171205.3T patent/ES2537527T3/es active Active
- 2006-09-20 EP EP20120171205 patent/EP2497780B1/en not_active Not-in-force
- 2006-09-20 DK DK12171205.3T patent/DK2497780T3/en active
- 2006-09-20 JP JP2008532384A patent/JP2009508532A/ja active Pending
-
2012
- 2012-03-28 JP JP2012073369A patent/JP2012149081A/ja not_active Withdrawn
- 2012-09-20 US US13/623,822 patent/US8911953B2/en not_active Expired - Fee Related
-
2014
- 2014-01-23 JP JP2014010456A patent/JP2014132900A/ja active Pending
- 2014-11-05 US US14/533,385 patent/US20150126451A1/en not_active Abandoned
-
2015
- 2015-07-10 CY CY20151100603T patent/CY1116742T1/el unknown
- 2015-10-20 JP JP2015206139A patent/JP2016047829A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014132900A5 (enExample) | ||
| JP2012019788A5 (enExample) | ||
| AU2022200142B2 (en) | Crystals of anti-human PD-1 monoclonal antibodies | |
| EP2900263B1 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
| TWI596112B (zh) | 抗－ｃｘｃｒ３抗體 | |
| JP6757712B2 (ja) | 幹細胞増強治療法 | |
| RU2004136981A (ru) | Антитела к рецептору igf-i | |
| EP2033971A1 (de) | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung | |
| TW201900682A (zh) | 抗ｐｈｆ－ｔａｕ抗體及其用途 | |
| UA125208C2 (uk) | Антитіло до cd40 | |
| UA125717C2 (uk) | Конструкція антитіла до flt3 і cd3 | |
| KR20130028050A (ko) | 유방암을 치료하는 방법 | |
| EP2928494A1 (en) | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES | |
| KR20140027051A (ko) | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 | |
| EA029956B1 (ru) | Кристаллы антител против склеростина и составы на их основе | |
| JP2025134707A (ja) | 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法 | |
| RU2015129720A (ru) | Антитела к h7cr | |
| JP2009508532A5 (enExample) | ||
| KR20240058050A (ko) | 아밀로이드 장애 치료를 위한 항체-펩티드 융합 단백질 | |
| JP6999809B2 (ja) | 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法 | |
| Testa et al. | Immunotargeting and cloning of two CD34 variants exhibiting restricted expression in adult rat endothelia in vivo | |
| US20090081221A1 (en) | Method for suppressing cancer cell metastasis and pharmaceutical composition for use in the method | |
| JP2010540660A (ja) | 哺乳類内の赤血球生成を刺激する新規の組成物および方法 | |
| CN118063610A (zh) | 靶向tim3的抗体及其核素标记物与应用 | |
| CN121263444A (zh) | 抗半乳糖凝集素3抗体和其在癫痫和相关疾病中的用途 |